Esperion Therapeutics Earnings Estimate
| ESPR Stock | USD 3.81 0.10 2.70% |
Esperion Therapeutics Revenue Breakdown by Earning Segment
By analyzing Esperion Therapeutics' earnings estimates, investors can diagnose different trends across Esperion Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Esperion Therapeutics' Gross Profit is relatively stable compared to the past year. As of 01/05/2026, Operating Profit Margin is likely to grow to 0.20, while Pretax Profit Margin is likely to drop (0.15). Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Esperion Therapeutics Earnings Estimation Breakdown
The calculation of Esperion Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Esperion Therapeutics is estimated to be -0.0067 with the future projection ranging from a low of -0.06 to a high of 0.07. Please be aware that this consensus of annual earnings estimates for Esperion Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.06 Lowest | Expected EPS | 0.07 Highest |
Esperion Therapeutics Earnings Projection Consensus
Suppose the current estimates of Esperion Therapeutics' value are higher than the current market price of the Esperion Therapeutics stock. In this case, investors may conclude that Esperion Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Esperion Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 8 | 57.64% | 0.0 | -0.0067 | -0.54 |
Esperion Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Esperion Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Esperion Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Esperion Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Esperion Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Esperion Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Esperion Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Esperion Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Esperion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | 0.02 | -0.16 | -0.18 | 900 | ||
2025-08-13 | 2025-06-30 | -0.14 | -0.06 | 0.08 | 57 | ||
2025-05-05 | 2025-03-31 | -0.15 | -0.2063 | -0.0563 | 37 | ||
2025-02-25 | 2024-12-31 | -0.1575 | -0.1013 | 0.0562 | 35 | ||
2024-11-05 | 2024-09-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2024-08-12 | 2024-06-30 | -0.18 | -0.33 | -0.15 | 83 | ||
2024-05-07 | 2024-03-31 | 0.05 | 0.34 | 0.29 | 580 | ||
2024-02-27 | 2023-12-31 | -0.48 | -0.5 | -0.02 | 4 | ||
2023-11-07 | 2023-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2023-08-01 | 2023-06-30 | -0.61 | -0.46 | 0.15 | 24 | ||
2023-05-09 | 2023-03-31 | -0.65 | -0.79 | -0.14 | 21 | ||
2023-02-21 | 2022-12-31 | -0.84 | -0.76 | 0.08 | 9 | ||
2022-11-01 | 2022-09-30 | -0.92 | -0.81 | 0.11 | 11 | ||
2022-08-02 | 2022-06-30 | -0.93 | -1.05 | -0.12 | 12 | ||
2022-05-03 | 2022-03-31 | -1.04 | -0.93 | 0.11 | 10 | ||
2022-02-22 | 2021-12-31 | -2.27 | -1.77 | 0.5 | 22 | ||
2021-11-02 | 2021-09-30 | -2.8 | -2.62 | 0.18 | 6 | ||
2021-08-03 | 2021-06-30 | -1.84 | -1.67 | 0.17 | 9 | ||
2021-05-04 | 2021-03-31 | -2.52 | -3.5 | -0.98 | 38 | ||
2021-02-23 | 2020-12-31 | -3.76 | -3.89 | -0.13 | 3 | ||
2020-11-02 | 2020-09-30 | -3.44 | -3.07 | 0.37 | 10 | ||
2020-08-10 | 2020-06-30 | 1.71 | 4.32 | 2.61 | 152 | ||
2020-05-06 | 2020-03-31 | -3.3 | -2.84 | 0.46 | 13 | ||
2020-02-27 | 2019-12-31 | -2.67 | -2.26 | 0.41 | 15 | ||
2019-11-06 | 2019-09-30 | -1.95 | -2.52 | -0.57 | 29 | ||
2019-08-08 | 2019-06-30 | -1.86 | -2.01 | -0.15 | 8 | ||
2019-05-08 | 2019-03-31 | 0.74 | 3.07 | 2.33 | 314 | ||
2019-02-28 | 2018-12-31 | -1.42 | -2.24 | -0.82 | 57 | ||
2018-11-01 | 2018-09-30 | -1.63 | -1.86 | -0.23 | 14 | ||
2018-08-02 | 2018-06-30 | -1.72 | -1.71 | 0.01 | 0 | ||
2018-05-02 | 2018-03-31 | -1.56 | -1.73 | -0.17 | 10 | ||
2018-02-20 | 2017-12-31 | -1.79 | -1.44 | 0.35 | 19 | ||
2017-11-07 | 2017-09-30 | -1.78 | -1.86 | -0.08 | 4 | ||
2017-08-08 | 2017-06-30 | -1.61 | -1.92 | -0.31 | 19 | ||
2017-05-04 | 2017-03-31 | -1.42 | -1.8 | -0.38 | 26 | ||
2017-02-22 | 2016-12-31 | -1.22 | -1.29 | -0.07 | 5 | ||
2016-11-03 | 2016-09-30 | -0.82 | -0.77 | 0.05 | 6 | ||
2016-08-04 | 2016-06-30 | -0.78 | -0.62 | 0.16 | 20 | ||
2016-05-04 | 2016-03-31 | -0.74 | -0.65 | 0.09 | 12 | ||
2016-02-25 | 2015-12-31 | -0.63 | -0.58 | 0.05 | 7 | ||
2015-11-05 | 2015-09-30 | -0.6 | -0.57 | 0.03 | 5 | ||
2015-08-06 | 2015-06-30 | -0.58 | -0.55 | 0.03 | 5 | ||
2015-05-07 | 2015-03-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2015-03-05 | 2014-12-31 | -0.55 | -0.49 | 0.06 | 10 | ||
2014-11-10 | 2014-09-30 | -0.68 | -0.64 | 0.04 | 5 | ||
2014-08-12 | 2014-06-30 | -0.6 | -0.6 | 0.0 | 0 | ||
2014-05-12 | 2014-03-31 | -0.62 | -0.51 | 0.11 | 17 | ||
2014-03-05 | 2013-12-31 | -0.5 | -0.63 | -0.13 | 26 | ||
2013-11-06 | 2013-09-30 | -0.4 | -0.34 | 0.06 | 15 |
About Esperion Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Esperion Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Esperion Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Esperion Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.4 B | -1.4 B | |
| Retained Earnings Total Equity | -1.2 B | -1.1 B | |
| Earnings Yield | (0.14) | (0.15) | |
| Price Earnings Ratio | (7.16) | (7.52) | |
| Price Earnings To Growth Ratio | 0.08 | 0.09 |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
Moving against Esperion Stock
| 0.71 | MSFT | Microsoft Sell-off Trend | PairCorr |
| 0.66 | PG | Procter Gamble | PairCorr |
| 0.63 | HD | Home Depot | PairCorr |
| 0.59 | HPQ | HP Inc | PairCorr |
| 0.4 | CVX | Chevron Corp | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.